Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

CORRECTING and REPLACING Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy

Fine Hygienic Holding

In the last sentence boilerplate of release dated April 11, 2022, "multiple accolated and awards" corrected to read "multiple awards". The updated release reads: Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy Fine Hygienic Holding (FHH), the world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has yet again taken the initiative to introduce new female-friendly policies as part of its continuous workplace reforms which aim to provide the most inclusive and welcoming environment possible for all its employees. Demonstrating that the company is serious about bringing about positive change, it has updated its Parental Leave Policy to include provisions for miscarriage or stillbirth, across all its locations. FHH already has generous maternity leave provisions for working mothers who benefit from 16 weeks of paid leave, above what the International Labour Organization recommends, and it even offers 3 weeks of paid paternity leave, which puts it at the forefront not only in the MENA region but also globally. Employees are eligible for compassionate leave upon the unfortunate event of a female employee or a male employee’s spouse suffering a miscarriage or stillbirth. In both instances the employee is entitled to five days of paid leave, and females may take an additional five days of unpaid leave. This comes in line with FHH’s core values to lead with empathy and extend leave to women needing time to recover physically and emotionally, and to consider the needs of male partners as well. No other company in the region offers such a generous leave policy, with provisions for maternity, paternity, miscarriage or stillbirth, in addition to a monthly day off for females. James Michael Lafferty, FHH CEO, said, “Our company believes that – if we take care of the people, the business will take care of itself – which is why we are constantly on the lookout for practices that support our employees’ wellbeing, especially during pivotal moments in their lives. With our updated policy our aim is to live our values and support our employees through difficult times.” FHH adheres to the highest standards of HR practices with a strong emphasis on supporting and empowering parents within its workforce. It is worth mentioning that the company was recently recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. About Fine Hygienic Holding: Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director Rkawalit@finehh.com Company Website https://www.finehh.com/

April 11, 2022 12:24 PM Eastern Daylight Time

Cannabis Education Event to Inform and Empower Consumers

MCR Labs

Local cannabis testing laboratory MCR Labs is hosting a consumer education event aimed at empowering consumers with the knowledge they need to make informed decisions about their cannabis purchases and consumption choices. The event, which is free and open to the public, will feature a presentation by MCR’s Vice President of Scientific Development Scott Churchill and InhaleMD’s President & CEO Dr. Jordan Tishler. Dr. Tishler is a Cannabinoid Specialist. “There is a lot of speculation out there on terms like ‘Total Active Cannabinoids’ and how factors like shelf life stability affect product quality,” said Churchill. “Our goal here is to help consumers develop a deeper understanding of cannabis so they can choose the right product for themselves.” MCR Labs provides analytical cannabis testing services to cultivators and product manufacturers. The data produced by these services, such as cannabinoid content, is often advertised on product labels. “It’s really important that patients understand how compounds like cannabinoids interact with their bodies,” said Dr. Tishler. “This can help them understand their medicine and work with their healthcare professionals to achieve optimal treatment.” Through his training in Internal Medicine and years of practice as an Emergency Physician, Dr. Tishler brings his knowledge, reason, and caring to patients at inhale MD, and through his advocacy work at the local and national levels. “What’s In Your Weed: The Educated Consumer” will be held this Thursday, April 14 from 6 to 8 p.m. at District Hall in Boston. Anyone interested in learning more or attending the event can find details on the event website. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

April 11, 2022 11:08 AM Eastern Daylight Time

Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy

Fine Hygienic Holding

Fine Hygienic Holding (FHH), the world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has yet again taken the initiative to introduce new female-friendly policies as part of its continuous workplace reforms which aim to provide the most inclusive and welcoming environment possible for all its employees. Demonstrating that the company is serious about bringing about positive change, it has updated its Parental Leave Policy to include provisions for miscarriage or stillbirth, across all its locations. FHH already has generous maternity leave provisions for working mothers who benefit from 16 weeks of paid leave, above what the International Labour Organization recommends, and it even offers 3 weeks of paid paternity leave, which puts it at the forefront not only in the MENA region but also globally. Employees are eligible for compassionate leave upon the unfortunate event of a female employee or a male employee’s spouse suffering a miscarriage or stillbirth. In both instances the employee is entitled to five days of paid leave, and females may take an additional five days of unpaid leave. This comes in line with FHH’s core values to lead with empathy and extend leave to women needing time to recover physically and emotionally, and to consider the needs of male partners as well. No other company in the region offers such a generous leave policy, with provisions for maternity, paternity, miscarriage or stillbirth, in addition to a monthly day off for females. James Michael Lafferty, FHH CEO, said, “Our company believes that – if we take care of the people, the business will take care of itself – which is why we are constantly on the lookout for practices that support our employees’ wellbeing, especially during pivotal moments in their lives. With our updated policy our aim is to live our values and support our employees through difficult times.” FHH adheres to the highest standards of HR practices with a strong emphasis on supporting and empowering parents within its workforce. It is worth mentioning that the company was recently recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple accolated and awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director Rkawalit@finehh.com Company Website https://www.finehh.com/

April 11, 2022 02:59 AM Eastern Daylight Time

Psychedelic Pharmaceutical Startup Ninnion Announces Patent Filings and Development of NIN-S119 for Ischemic Stroke

Ninnion

Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics, today announced the commencement of a first-of-its-kind pre-clinical development of NIN-S119. NIN-S119 is a proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke. It would be the first drug of its kind in the treatment of stroke, potentially making it eligible for Breakthrough Therapy designation by the FDA, a designation that can accelerate the development timeline. “Ninnion saw a big opportunity to develop NIN-S119, as there are no approved drug therapies for patients recovering from a stroke. It will be used in conjunction with physical/occupational therapy to enhance stroke recovery by inducing neuroplasticity – meaning it induces the formation of new connections between nerve cells in the brain. This sort of brain ‘rewiring’ could prove beneficial for stroke recovery by creating new brain circuitry that could restore function to brain areas damaged by stroke,” said Bill W Massey, Chief Development Officer of Ninnion. While drugs of this class that produce neuroplastic effects can induce psychedelic experiences (e.g. LSD, mescaline, DMT, etc.), one major benefit of NIN-S119 is that even though it's in this class of drugs, it could potentially be administered in low doses that do not produce these experiences. This would make NIN-S119 much easier to use clinically, reducing the time and effort of clinical staff and opening the potential for administration by the patient at home. “After experiencing multiple health issues, including three strokes in one year, I began researching and reading all about how to repair the brain through the neuroplasticity and neurogenesis effects of psychedelics. We created Ninnion to not only develop a new way to treat strokes but more importantly, to bring these drugs to market in a responsible way. The way psychedelic therapies are set up now is not helpful for the payer-reimbursed market. We want to create therapies that are accessible and affordable; patients should not have to pay thousands of dollars for therapies out of pocket. We’re encouraged by recent patent approvals for the development and delivery of new psychedelic therapies and we’re looking forward to advancing our clinical trials and continuing to develop other molecules in our pipeline,” said Jeremy M Caudill, Founder, and CEO of Ninnion. Ninnion’s research and development efforts currently focus on advancing next-generation psychedelic therapies, which will ultimately empower patients with more accessible and affordable treatment opportunities. To find out more about the study and Ninnion’s NIN-S119 molecule, visit www.ninnion.com/. About Ninnion Headquartered in Austin, Texas, Ninnion is a pharmaceutical company on a mission to build a fully integrated pharmaceutical psychedelics eco-system leveraging the latest AI drug discovery, development, cGMP manufacturing, commercialization, patient clinics and specialty pharmacy distribution network designed for the next frontier of psychedelic medicine. Focused on the payer-reimbursed market, Ninnion has begun developing a pipeline of next generation psychedelic therapies with a clinical focus on brain injury, chronic pain, inflammation, and addiction disorders. To learn more, visit www.ninnion.com. Contact Details Jive PR + Digital Ashley Areeda +1 734-891-4013 aareeda@jiveprdigital.com

April 07, 2022 11:33 AM Eastern Daylight Time

COD Mammography Program Acquires Cutting-Edge, Hospital-Grade Equipment

College of DuPage

Mammography program students at College of DuPage now have access to more specialized training, thanks for the addition of new field-specific equipment. The innovative digital technology, Hologic Tomosynthesis 2D and 3D mammography machines, typically are available at hospitals and clinical settings and rarely on a college campus, said COD Diagnostic Medical Imaging Assistant Professor and Mammography Program Chair Sue Dumford. “The new equipment gives students an added advantage to be able to practice their skills in the classroom before having to use it on real patients during clinical rotations at hospitals and clinics,” she said. “Students will be able to practice on other classmates as well as on model torsos with soft breasts. Having the machines in front of students also allows us to teach about quality assurance and quality control.” The Mammography program at COD is a one-semester post-radiography advanced certificate program available to graduates of an accredited Radiography program. Many of the students enrolled in the Mammography program are graduates of COD’s two-year Radiography program. "I’m proud to say that we maintain a 100 percent American Registry of Radiologic Technologists registry pass rate and that our graduates are recognized as excellent entry-level mammographers,” Dumford said. Tara Logan decided to pursue a career in mammography after working at the front desk of a general surgery office. “One of the doctors in my office was a breast surgeon,” she said. “Every day he worked with breast cancer patients, and I will never forget how he made them feel. When people are going through some of the toughest days of their life, they need someone to lean on, and I wanted to be that person for them.” Logan graduated from COD’s Radiography program in 2020 earning an Associate in Applied Science in Diagnostic Medical Imaging before earning an advanced certificate in Mammography in 2021. “The program truly prepared me for a long career in breast imaging, and I’m so lucky to have been a part of both COD’s Radiography and Mammography programs,” she said. “With the two mammography units, I was able to learn correct positioning skills and then go out into the field and practice on real patients. Cancer screening is something that will always be needed, and your patients will always need you. Apply to the program and start making a difference in the way females feel about health care.” Learn more about the COD Mammography program. Learn more about COD’s Radiography program. Contact Details College of DuPage Angela Mennecke +1 630-942-3134 menneckea@cod.edu

April 07, 2022 08:00 AM Central Daylight Time

Image

Cloudrise Is Taking 2022 By Storm

Cloudrise

Cloudrise Inc., a technology-enabled services firm focused on data protection, cloud security, and privacy, continues to make waves with a flurry of exciting news to kick-off 2022. Cloudrise is pleased to announce the acquisition of CyberOrchard, an information security managed service organization located in the United Kingdom. Cloudrise CEO, Rob Eggebrecht, shared his thoughts: “The merger of the two companies brings a breadth of knowledge and expertise to Cloudrise, paving the way to expand our portfolio of data protection services to the global market.” As part of the acquisition, Jason Bird, CyberOrchard’s Founder and CEO, has been named Chief Technology Officer (CTO) at Cloudrise. Bird has over 25 years of experience in cybersecurity, managed services, data governance, and privacy. “Data protection is becoming more complex every day, and at Cloudrise we believe collaboration is the path to better protection for our customers. We are partnering with the strongest data-centric technology companies to bring innovative solutions to our customers, such as Netskope, AWS, Digital Guardian, Microsoft, OneTrust, Varonis, BigID, and Veritas, just to name a few,” said Bird. This news comes just a week after Netskope named Cloudrise as their Global Services Partner of the Year. “This achievement illustrates Cloudrise’s commitment to delivering innovative service offerings to customers worldwide,” said Joe Infantino, Chief Operating Officer at Cloudrise. Additionally, Cloudrise is pleased to announce that CRN®, a brand of The Channel Company, has named Cloudrise to its Managed Service Provider (MSP) 500 list in the Managed Security 100 category for 2022. Winners are recognized for helping end users increase efficiency, simplify solutions, and maximize their return on investment. Cloudrise is taking 2022 by storm and encourages its followers to stay tuned for future announcements. About Cloudrise Cloudrise is a technology-enabled services firm, specializing in delivering data-centric services customized to meet organizations’ business needs. Drawing from 20+ years of experience in the field, they have tailored their services to be focused on securing organizations’ data wherever it resides. Cloudrise knows how to identify gaps, build and optimize controls and integrations across the enterprise, and deploy data-centric technologies across multiple industries, geographies and organizational sizes – all with the expertise to navigate an ever-changing data compliance and regulatory landscape. Cloudrise can be found at Cloudrise.com or on LinkedIn. About CyberOrchard UK-based CyberOrchard is an information security managed services organization, home to experts with over 20 years of data security experience. Whether the risk to organizations' data lives in transit on the network, at rest in storage, or in use at an endpoint, CyberOrchard provides the necessary data security bundled service offerings, consultancy and managed services to significantly reduce organizations' risk of data loss. CyberOrchard can be found at cyberorchard.com or on LinkedIn. Contact Details Jodi Lewis +1 800-917-7619 sales@cloudrise.com Company Website https://cloudrise.com/

April 06, 2022 07:00 AM Mountain Daylight Time

Lancer Dermatology Announces Partnership with Forefront Dermatology

Lancer

Premier Beverly Hills-based dermatology practice, Lancer Dermatology, announced today that it has partnered with Forefront Dermatology, the largest physician-led single specialty group providing dermatological services in the United States with over 200+ dermatology practices. The collaboration with Forefront Dermatology will serve to expand the world-renowned legacy of the Lancer Dermatology practice through satellite clinics in select additional markets across the United States. Since opening the clinic in 1983, Dr. Harold Lancer has grown his Beverly Hills-based dermatology practice into a world-renowned mecca with a celebrity cult-following. Currently, the practice is a global destination for celebrities, socialites, and even members of royal families. Dr. Lancer’s work ethic, integrity, approach, and results make him one of the most sought-out dermatology professionals, piquing the interest of Forefront Dermatology. The team at Lancer Dermatology consists of tenured nurses and skilled aestheticians who have been personally trained by Dr. Lancer to deliver the highest level of service and care to their patients. The partnership between Lancer Dermatology and Forefront Dermatology will allow the legacy and state-of-the-art care that Lancer Dermatology is known for worldwide, to expand beyond the Beverly Hills clinic for many years to come. By opening satellite locations across the nation, even more patients will be able to experience the state-of-the-art care that Lancer Dermatology is celebrated for, even if they are unable to visit the Beverly Hills practice. “The highlight of my career was when I opened the doors to my Beverly Hills clinic in 1983, and every day since then I have had the pleasure of treating my patients with unparalleled care. I am proud to partner with Forefront Dermatology to extend the legacy we have created at Lancer Dermatology to make our state-of-the-art experience and treatments even more accessible,” said Dr. Harold Lancer, Board-Certified Dermatologist and Founder of Lancer Dermatology and Lancer Skincare. “For many years, we have had the goal to extend the state-of-the-art approach of Lancer Dermatology practice beyond the Beverly Hills clinic. When Forefront Dermatology approached our team, it was clear that their preeminent expertise in expansion was in perfect alignment with our goals. Through this partnership, we are thrilled to be expanding our legacy, without sacrificing on quality of care,” said Tracey Sameyah, CEO of Lancer Skincare. “Our partnership with Dr. Lancer and the Lancer Dermatology Team is consistent with our approach to partnering with Board-Certified Dermatologists and Surgeons that are committed to physician leadership, innovation, and exceptional patient experiences and outcomes. We are thrilled to partner with Dr. Lancer on expanding access to dermatology care and leveraging the expertise and strong reputation he has garnered over the past 30 years,” said Betsy J. Wernli, MD, President of Forefront Dermatology. The Beverly Hills clinic will remain unaffected by the partnership, with no changes being made to the day-to-day operations or existing staff of distinguished nurses and aestheticians. Dr. Lancer’s international skincare brand, Lancer Skincare, will also remain a separate entity, owned solely by Dr. Lancer, with no changes to the award-winning products that bring to life his philosophy of “from practice to product.” Lancer Dermatology is moving faster than ever to make its state-of-the-art care and approach more accessible and available to everyone. For more information about Lancer Dermatology, please visit LancerSkincare.com or @drlancerrx. About Lancer Dermatology The goal at Lancer Dermatology is to provide each patient with expert skin care and a personalized, first-class experience. Lancer Dermatology offers state-of-the-art care in aesthetic, cosmetic, medical and surgical dermatology treatments. The Lancer Dermatology team consists of tenured nurses who have been personally trained by Dr. Lancer to deliver the highest level of service and care to our patients. Dr. Lancer believes that the best way to foster trust and commitment amongst patients is to have a knowledgeable and familiar team at his side. The Lancer Nursing Team is an elite and talented group of professionals who are always on hand to assist with all patient consultations and procedures. Dr. Lancer's skilled aestheticians possess decades of experience providing customized services and treatments to patients. Trained by Dr. Lancer himself, the aesthetician team is comprised of multilingual, highly-professional and sought-after experts who are proficient in The Lancer Method protocols as well as all of the Services & Technologies offered exclusively at the Lancer Dermatology Clinic. With revolutionized procedures and tools, the team is able to provide a personalized, best-in-class experience to every patient. About Forefront Dermatology Located throughout the East, Midwest, Mid-Atlantic, Southwest, Southeast and West, Forefront Dermatology is a large and growing, physician-led, single-specialty group practice comprising 200+ dermatology practices. Forefront's community-based, Board-Certified Dermatologists and specialists provide best-in-class general, surgical and cosmetic dermatological care along with related laboratory services. Headquartered in Manitowoc, WI, Forefront's Board-Certified Dermatologists and medical specialists are dedicated to providing the highest standard of care for conditions of the hair, skin, and nails to people of all ages and stages of life. Using innovative and proven solutions, Forefront's caring, Board-Certified Dermatologists and medical specialists treat the total patient to help improve not only the condition of their skin, but also their quality of life. To learn more, visit www.ForefrontDermatology.com. Contact Details OGAKI Malinda Torres +1 646-475-7056 mtorres@ogakidigital.com Company Website https://www.lancerskincare.com/

April 04, 2022 09:00 AM Eastern Daylight Time

Green Cubes Technology Announces Membership in CircuBAT Research Program

Green Cubes Technology

Green Cubes Technology, a leader in electrification and Lithium power solutions, today announced its participation as a founding member in CircuBAT. CircuBAT is a Swiss research program that aims to create a Swiss circular business model for the production, application, and recycling of Lithium-ion batteries. Seven Swiss research institutions and 24 companies are joining forces to look for ways to boost sustainability in all stages of a battery’s life cycle. CircuBAT will focus on finding solutions that boost sustainability in all phases of a Lithium-ion battery’s life cycle. This will include extending the lifespan of batteries during their first application. Researchers hope to achieve this by developing optimal charging and discharging strategies as well as new concepts for battery construction that make repairs easy. The project also aims to put batteries to use as stationary energy storage systems after they are retired from their first mobility-related application. To that end, CircuBAT will look at the best ways of integrating these batteries at a local level and ensuring their safe and efficient operation. Finally, the researchers will look for solutions for remanufacturing batteries and recovering materials that enable large quantities of high-quality secondary raw materials to be used to produce new batteries. Bern University of Applied Sciences BFH is the Leading House in the CircuBAT project. On the science side, an additional six Swiss research institutions are involved in the project: Empa, the Swiss Center for Electronics and Microtechnology (CSEM), the University of St. Gallen (HSG), the Eastern Switzerland University of Applied Sciences (OST), the Switzerland Innovation Park Biel / Bienne (SIPBB) and the EPFL (Swiss Federal Institute of Technology). These institutions are joined by 24 companies from economy and industry, among them Kyburz, Leclanché, Bühler and Green Cubes Technology. As a founding member of CircuBAT, Green Cubes Technology has made a multi-year financial investment in the program. The company will also contribute first-use lithium-ion batteries for experimentation and testing within the program, provide engineering design services to develop new more-efficient batteries, and contribute intellectual property to achieve the objectives of CircuBAT. Green Cubes Technology will participate in two working groups. The “First Use” group will focus on extending the life of first-use batteries through extensive analysis of deployed batteries in the field. Green Cubes Technology will contribute performance data collected from its prolific installed base of Lithium-ion batteries. The “Second Life” group will focus on creating second-use and second-life opportunities to minimize the total CO 2 footprint of lithium-ion battery systems during their lifetime. Since its inception 30 years ago, Green Cubes Technology has gained considerable experience minimizing the environmental impact of its deployed batteries. This positive impact will be amplified with a system of second life batteries, where the installed base of first use batteries is redeployed when they reach a certain age limit. The Lithium-ion cells used in Green Cubes Technology’s batteries are non-toxic, and are currently recycled and reprocessed at their end of life. Going forward, these cells can be repurposed into less demanding second life applications such as backup energy storage. “We joined the CircuBAT research program because its mission is very well aligned with ours,” said Keith Washington, CEO of Green Cubes Technology. “We all want the same thing and that is a circular economy for Lithium-ion batteries. We are looking forward to sharing our experience, and giving electric mobility batteries a second life with our Swiss partners in the CircuBAT research program, as they strive to make the Swiss economy as sustainable as possible” More information on the research program can be found on its website: https://circubat.ch. About Green Cubes Technology Green Cubes Technology develops and manufactures safe and reliable electrification solutions that enable its OEM and enterprise customers to transition from Lead Acid and Internal Combustion Engine (ICE) power to Lithium-ion battery power. Green Cubes utilizes proven hardware and software platforms to build the most reliable Lithium power solutions in its industries. With over 300 employees across six countries, Green Cubes has been producing innovative, high-performance and high-quality power solutions since 1986. More information can be found at https://greencubestech.com. Contact Details Ray Young (General Media, Investor Relations) +1 916-505-4245 ray@razorsharppr.com Hayley Luz (Trade Media) +1 425-918-2742 hluz@greencubestech.com Company Website https://greencubestech.com/

March 31, 2022 10:00 AM Eastern Daylight Time

CORRECTING and REPLACING G Medical Innovations takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity

G Medical Innovations Holdings

This release issued on March 30, 2022 is being replaced with the following corrected version due to multiple revisions. The updated release reads: G Medical Innovations (NASDAQ: GMVD) takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity Poised for expansion and growth, the company continues to process thousands of COVID-19 PCR and rapid antigen/flu testing; and its personal healthcare monitoring business expects sales growth G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity and ensure perpetrators will face aggressive legal action in the interest of protecting shareholders. G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) announced that it has investigated aggressive naked short sales of its stock and is confident that it has identified the perpetrators of this illegal activity. The company will defend its shareholders by taking all regulatory and legal action against this criminal activity. It has instructed its legal department to contact the SEC, FINRA, and NASDAQ to conduct full investigations on their ends. G Medical continues to demonstrate growth and commitment to expansion across its business units. Its wholly owned subsidiary, G Medical Tests and Services, Inc. as well as G-Medical Lab Services Inc., continues to process thousands of COVID-19 PCR and rapid antigen/flu tests from its sites and its personal healthcare monitoring business expects sales growth via negotiations with major health systems and is prepared for increased testing capacity, given new virus variants expected to emerge. In addition, G Medical Innovations is involved in negotiations with numerous hospitals and healthcare systems for sales of its Prizma Care remote patient monitoring devices and services. Patients, cardiologists, and health providers across the country rely on G Medical’s innovative Prizma monitoring devices and services for accurate and reliable remote monitoring. The company is planning a shareholder’s conference call soon. At that time, it will report on achievements during Q1 2022. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial-stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses that it continues to process thousands of COVID-19 PCR and rapid antigen/flu tests from its sites and is prepared for increased testing capacity, given new virus variants expected to emerge. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, the registration statement on Form F-1 filed on February 14, 2022 (registration no. 333-262724) and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

March 30, 2022 12:26 PM Eastern Daylight Time

1 ... 190 191 192 193 194 ... 250